APO Research
Talk to an analyst

APO RESEARCH · REPORT

Hepatic Encephalopathy Drugs

Compare research editions
View pricing & licenses

Selected research

Market Analysis & Forecast

Global Hepatic Encephalopathy Drugs Market Analysis and Forecast 2026-2032

20 December 2025193 pages

Choose your research edition.

Industry ResearchHepatic Encephalopathy Drugs Industry Research Report 2026126 pages · $2,950 USDIndustry Growth & TrendsGlobal Hepatic Encephalopathy Drugs Industry Growth and Trends Forecast to 2032100 pages · $3,450 USDMarket StructureGlobal Hepatic Encephalopathy Drugs Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032199 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Hepatic Encephalopathy Drugs Market Outlook and Growth Opportunities 2026196 pages · $4,250 USDMarket Analysis & ForecastGlobal Hepatic Encephalopathy Drugs Market Analysis and Forecast 2026-2032193 pages · $4,950 USD

Market perspective

The global Hepatic Encephalopathy Drugs market is projected to grow from US$ million in 2026 to US$ million by 2032, at a Compound Annual Growth Rate (CAGR) of % during the forecast period.

The US & Canada market for Hepatic Encephalopathy Drugs is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

Europe market for Hepatic Encephalopathy Drugs is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

Read the full market overview

Asia-Pacific market for Hepatic Encephalopathy Drugs is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

The China market for Hepatic Encephalopathy Drugs is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

The major global manufacturers of Hepatic Encephalopathy Drugs include Umecrine Cognition, Norgine, Mallinckrodt, Lupin, Kannalife Sciences, Kaleido Biosciences, Ferring Pharmaceuticals, Cosmo Pharmaceuticals and Bausch Health, etc. In 2025, the world's top three vendors accounted for approximately % of the revenue.

This report presents an overview of global market for Hepatic Encephalopathy Drugs, sales, revenue and price. Analyses of the global market trends, with historic market revenue or sales data for 2021 - 2025, estimates for 2026, and projections of CAGR through 2032.

This report researches the key producers of Hepatic Encephalopathy Drugs, also provides the sales of main regions and countries. Of the upcoming market potential for Hepatic Encephalopathy Drugs, and key regions or countries of focus to forecast this market into various segments and sub-segments. Country specific data and market value analysis for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, Middle East, Africa, and Other Countries.

This report focuses on the Hepatic Encephalopathy Drugs sales, revenue, market share and industry ranking of main manufacturers, data from 2021 to 2026. Identification of the major stakeholders in the global Hepatic Encephalopathy Drugs market, and analysis of their competitive landscape and market positioning based on recent developments and segmental revenues. This report will help stakeholders to understand the competitive landscape and gain more insights and position their businesses and market strategies in a better way.

This report analyzes the segments data by Type and by Application, sales, revenue, and price, from 2021 to 2032. Evaluation and forecast the market size for Hepatic Encephalopathy Drugs sales, projected growth trends, production technology, application and end-user industry.

Hepatic Encephalopathy Drugs Segment by Company

Umecrine Cognition

Norgine

Mallinckrodt

Lupin

Kannalife Sciences

Kaleido Biosciences

Ferring Pharmaceuticals

Cosmo Pharmaceuticals

Bausch Health

ASKA Pharmaceutical

Hepatic Encephalopathy Drugs Segment by Type

Injection

Oral

Hepatic Encephalopathy Drugs Segment by Application

Hospital Pharmacies

Online Pharmacies

Retail Pharmacies

Hepatic Encephalopathy Drugs Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Study Objectives

1. To analyze and research the global status and future forecast, involving growth rate (CAGR), market share, historical and forecast.

2. To present the key manufacturers, sales, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify significant trends, drivers, influence factors in global and regions.

6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Hepatic Encephalopathy Drugs market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Hepatic Encephalopathy Drugs and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Hepatic Encephalopathy Drugs.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by type and by application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.

Chapter 2: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 3: Sales (consumption), revenue of Hepatic Encephalopathy Drugs in global, regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space of each country in the world.

Chapter 4: Detailed analysis of Hepatic Encephalopathy Drugs manufacturers competitive landscape, price, sales, revenue, market share and industry ranking, latest development plan, merger, and acquisition information, etc.

Chapter 5: Provides the analysis of various market segments by type, covering the sales, revenue, average price, and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 6: Provides the analysis of various market segments by application, covering the sales, revenue, average price, and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 7: Provides profiles of key manufacturers, introducing the basic situation of the main companies in the market in detail, including product descriptions and specifications, Hepatic Encephalopathy Drugs sales, revenue, price, gross margin, and recent development, etc.

Chapter 8: North America by type, by application and by country, sales, and revenue for each segment.

Chapter 9: Europe by type, by application and by country, sales, and revenue for each segment.

Chapter 10: China type, by application, sales, and revenue for each segment.

Chapter 11: Asia (excluding China) type, by application and by region, sales, and revenue for each segment.

Chapter 12: South America, Middle East and Africa by type, by application and by country, sales, and revenue for each segment.

Chapter 13: Analysis of industrial chain, sales channel, key raw materials, distributors and customers.

Chapter 14: The main concluding insights of the report.

More report detail

Tables and figures
List of Tables Table 1. Global Hepatic Encephalopathy Drugs Market Size Growth Rate by Type (US$ Million), 2021 VS 2025 VS 2032 Table 2. Injection Major Manufacturers Table 3. Oral Major Manufacturers Table 4. Global Hepatic Encephalopathy Drugs Market Size Growth Rate by Application (US$ Million), 2021 VS 2025 VS 2032 Table 5. Hospital Pharmacies Major Manufacturers Table 6. Online Pharmacies Major Manufacturers Table 7. Retail Pharmacies Major Manufacturers Table 8. Hepatic Encephalopathy Drugs Industry Trends Table 9. Hepatic Encephalopathy Drugs Industry Drivers Table 10. Hepatic Encephalopathy Drugs Industry Opportunities and Challenges Table 11. Hepatic Encephalopathy Drugs Industry Restraints Table 12. Global Hepatic Encephalopathy Drugs Revenue Grow Rate (CAGR) by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 13. Global Hepatic Encephalopathy Drugs Revenue by Region (2021-2026) & (US$ Million) Table 14. Global Hepatic Encephalopathy Drugs Revenue by Region (2027-2032) & (US$ Million) Table 15. Global Hepatic Encephalopathy Drugs Revenue Market Share by Region (2021-2026) Table 16. Global Hepatic Encephalopathy Drugs Revenue Market Share by Region (2027-2032) Table 17. Global Hepatic Encephalopathy Drugs Sales Grow Rate (CAGR) by Region: 2021 VS 2025 VS 2032 (tons) Table 18. Global Hepatic Encephalopathy Drugs Sales by Region (2021-2026) & (tons) Table 19. Global Hepatic Encephalopathy Drugs Sales by Region (2027-2032) & (tons) Table 20. Global Hepatic Encephalopathy Drugs Sales Market Share by Region (2021-2026) Table 21. Global Hepatic Encephalopathy Drugs Sales Market Share by Region (2027-2032) Table 22. Global Hepatic Encephalopathy Drugs Revenue by Manufacturers (US$ Million) & (2021-2026) Table 23. Global Hepatic Encephalopathy Drugs Revenue Market Share by Manufacturers (2021-2026) Table 24. Global Hepatic Encephalopathy Drugs Sales by Manufacturers (US$ Million) & (2021-2026) Table 25. Global Hepatic Encephalopathy Drugs Sales Market Share by Manufacturers (2021-2026) Table 26. Global Hepatic Encephalopathy Drugs Sales Price (US$/kg) of Manufacturers (2021-2026) Table 27. Global Hepatic Encephalopathy Drugs Key Manufacturers Ranking, 2024 VS 2025 VS 2026 Table 28. Global Hepatic Encephalopathy Drugs Key Manufacturers Manufacturing Sites & Headquarters Table 29. Global Hepatic Encephalopathy Drugs Manufacturers, Product Type & Application Table 30. Global Hepatic Encephalopathy Drugs Manufacturers' Establishment Date Table 31. Global Manufacturers Market Concentration Ratio (CR5 and HHI) Table 32. Global Hepatic Encephalopathy Drugs by Manufacturers Type (Tier 1, Tier 2, and Tier 3) & (Based on the Revenue of 2025) Table 33. Global Hepatic Encephalopathy Drugs Revenue by Type 2021 VS 2025 VS 2032 (US$ Million) Table 34. Global Hepatic Encephalopathy Drugs Revenue by Type (2021-2026) & (US$ Million) Table 35. Global Hepatic Encephalopathy Drugs Revenue by Type (2027-2032) & (US$ Million) Table 36. Global Hepatic Encephalopathy Drugs Revenue Market Share by Type (2021-2026) Table 37. Global Hepatic Encephalopathy Drugs Revenue Market Share by Type (2027-2032) Table 38. Global Hepatic Encephalopathy Drugs Sales by Type 2021 VS 2025 VS 2032 (tons) Table 39. Global Hepatic Encephalopathy Drugs Sales by Type (2021-2026) & (tons) Table 40. Global Hepatic Encephalopathy Drugs Sales by Type (2027-2032) & (tons) Table 41. Global Hepatic Encephalopathy Drugs Sales Market Share by Type (2021-2026) Table 42. Global Hepatic Encephalopathy Drugs Sales Market Share by Type (2027-2032) Table 43. Global Hepatic Encephalopathy Drugs Price by Type (2021-2026) & (US$/kg) Table 44. Global Hepatic Encephalopathy Drugs Price by Type (2027-2032) & (US$/kg) Table 45. Global Hepatic Encephalopathy Drugs Revenue by Application 2021 VS 2025 VS 2032 (US$ Million) Table 46. Global Hepatic Encephalopathy Drugs Revenue by Application (2021-2026) & (US$ Million) Table 47. Global Hepatic Encephalopathy Drugs Revenue by Application (2027-2032) & (US$ Million) Table 48. Global Hepatic Encephalopathy Drugs Revenue Market Share by Application (2021-2026) Table 49. Global Hepatic Encephalopathy Drugs Revenue Market Share by Application (2027-2032) Table 50. Global Hepatic Encephalopathy Drugs Sales by Application 2021 VS 2025 VS 2032 (tons) Table 51. Global Hepatic Encephalopathy Drugs Sales by Application (2021-2026) & (tons) Table 52. Global Hepatic Encephalopathy Drugs Sales by Application (2027-2032) & (tons) Table 53. Global Hepatic Encephalopathy Drugs Sales Market Share by Application (2021-2026) Table 54. Global Hepatic Encephalopathy Drugs Sales Market Share by Application (2027-2032) Table 55. Global Hepatic Encephalopathy Drugs Price by Application (2021-2026) & (US$/kg) Table 56. Global Hepatic Encephalopathy Drugs Price by Application (2027-2032) & (US$/kg) Table 57. Umecrine Cognition Company Information Table 58. Umecrine Cognition Business Overview Table 59. Umecrine Cognition Hepatic Encephalopathy Drugs Sales (tons), Revenue (US$ Million), Price (US$/kg) and Gross Margin (2021-2026) Table 60. Umecrine Cognition Hepatic Encephalopathy Drugs Product Portfolio Table 61. Umecrine Cognition Recent Development Table 62. Norgine Company Information Table 63. Norgine Business Overview Table 64. Norgine Hepatic Encephalopathy Drugs Sales (tons), Revenue (US$ Million), Price (US$/kg) and Gross Margin (2021-2026) Table 65. Norgine Hepatic Encephalopathy Drugs Product Portfolio Table 66. Norgine Recent Development Table 67. Mallinckrodt Company Information Table 68. Mallinckrodt Business Overview Table 69. Mallinckrodt Hepatic Encephalopathy Drugs Sales (tons), Revenue (US$ Million), Price (US$/kg) and Gross Margin (2021-2026) Table 70. Mallinckrodt Hepatic Encephalopathy Drugs Product Portfolio Table 71. Mallinckrodt Recent Development Table 72. Lupin Company Information Table 73. Lupin Business Overview Table 74. Lupin Hepatic Encephalopathy Drugs Sales (tons), Revenue (US$ Million), Price (US$/kg) and Gross Margin (2021-2026) Table 75. Lupin Hepatic Encephalopathy Drugs Product Portfolio Table 76. Lupin Recent Development Table 77. Kannalife Sciences Company Information Table 78. Kannalife Sciences Business Overview Table 79. Kannalife Sciences Hepatic Encephalopathy Drugs Sales (tons), Revenue (US$ Million), Price (US$/kg) and Gross Margin (2021-2026) Table 80. Kannalife Sciences Hepatic Encephalopathy Drugs Product Portfolio Table 81. Kannalife Sciences Recent Development Table 82. Kaleido Biosciences Company Information Table 83. Kaleido Biosciences Business Overview Table 84. Kaleido Biosciences Hepatic Encephalopathy Drugs Sales (tons), Revenue (US$ Million), Price (US$/kg) and Gross Margin (2021-2026) Table 85. Kaleido Biosciences Hepatic Encephalopathy Drugs Product Portfolio Table 86. Kaleido Biosciences Recent Development Table 87. Ferring Pharmaceuticals Company Information Table 88. Ferring Pharmaceuticals Business Overview Table 89. Ferring Pharmaceuticals Hepatic Encephalopathy Drugs Sales (tons), Revenue (US$ Million), Price (US$/kg) and Gross Margin (2021-2026) Table 90. Ferring Pharmaceuticals Hepatic Encephalopathy Drugs Product Portfolio Table 91. Ferring Pharmaceuticals Recent Development Table 92. Cosmo Pharmaceuticals Company Information Table 93. Cosmo Pharmaceuticals Business Overview Table 94. Cosmo Pharmaceuticals Hepatic Encephalopathy Drugs Sales (tons), Revenue (US$ Million), Price (US$/kg) and Gross Margin (2021-2026) Table 95. Cosmo Pharmaceuticals Hepatic Encephalopathy Drugs Product Portfolio Table 96. Cosmo Pharmaceuticals Recent Development Table 97. Bausch Health Company Information Table 98. Bausch Health Business Overview Table 99. Bausch Health Hepatic Encephalopathy Drugs Sales (tons), Revenue (US$ Million), Price (US$/kg) and Gross Margin (2021-2026) Table 100. Bausch Health Hepatic Encephalopathy Drugs Product Portfolio Table 101. Bausch Health Recent Development Table 102. ASKA Pharmaceutical Company Information Table 103. ASKA Pharmaceutical Business Overview Table 104. ASKA Pharmaceutical Hepatic Encephalopathy Drugs Sales (tons), Revenue (US$ Million), Price (US$/kg) and Gross Margin (2021-2026) Table 105. ASKA Pharmaceutical Hepatic Encephalopathy Drugs Product Portfolio Table 106. ASKA Pharmaceutical Recent Development Table 107. North America Hepatic Encephalopathy Drugs Revenue by Type (2021-2026) & (US$ Million) Table 108. North America Hepatic Encephalopathy Drugs Revenue by Type (2027-2032) & (US$ Million) Table 109. North America Hepatic Encephalopathy Drugs Sales by Type (2021-2026) & (tons) Table 110. North America Hepatic Encephalopathy Drugs Sales by Type (2027-2032) & (tons) Table 111. North America Hepatic Encephalopathy Drugs Sales Price by Type (2021-2026) & (US$/kg) Table 112. North America Hepatic Encephalopathy Drugs Sales Price by Type (2027-2032) & (US$/kg) Table 113. North America Hepatic Encephalopathy Drugs Revenue by Application (2021-2026) & (US$ Million) Table 114. North America Hepatic Encephalopathy Drugs Revenue by Application (2027-2032) & (US$ Million) Table 115. North America Hepatic Encephalopathy Drugs Sales by Application (2021-2026) & (tons) Table 116. North America Hepatic Encephalopathy Drugs Sales by Application (2027-2032) & (tons) Table 117. North America Hepatic Encephalopathy Drugs Sales Price by Application (2021-2026) & (US$/kg) Table 118. North America Hepatic Encephalopathy Drugs Sales Price by Application (2027-2032) & (US$/kg) Table 119. North America Hepatic Encephalopathy Drugs Revenue Grow Rate by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 120. North America Hepatic Encephalopathy Drugs Revenue Grow Rate by Country (2021-2026) & (US$ Million) Table 121. North America Hepatic Encephalopathy Drugs Revenue Grow Rate by Country (2027-2032) & (US$ Million) Table 122. North America Hepatic Encephalopathy Drugs Sales by Country (2021 VS 2025 VS 2032) & (tons) Table 123. North America Hepatic Encephalopathy Drugs Sales by Country (2021-2026) & (tons) Table 124. North America Hepatic Encephalopathy Drugs Sales by Country (2027-2032) & (tons) Table 125. North America Hepatic Encephalopathy Drugs Sales Price by Country (2021-2026) & (US$/kg) Table 126. North America Hepatic Encephalopathy Drugs Sales Price by Country (2027-2032) & (US$/kg) Table 127. United States Hepatic Encephalopathy Drugs Revenue (2021-2032) & (US$ Million) Table 128. Canada Hepatic Encephalopathy Drugs Revenue (2021-2032) & (US$ Million) Table 129. Mexico Hepatic Encephalopathy Drugs Revenue (2021-2032) & (US$ Million) Table 130. Europe Hepatic Encephalopathy Drugs Revenue by Type (2021-2026) & (US$ Million) Table 131. Europe Hepatic Encephalopathy Drugs Revenue by Type (2027-2032) & (US$ Million) Table 132. Europe Hepatic Encephalopathy Drugs Sales by Type (2021-2026) & (tons) Table 133. Europe Hepatic Encephalopathy Drugs Sales by Type (2027-2032) & (tons) Table 134. Europe Hepatic Encephalopathy Drugs Sales Price by Type (2021-2026) & (US$/kg) Table 135. Europe Hepatic Encephalopathy Drugs Sales Price by Type (2027-2032) & (US$/kg) Table 136. Europe Hepatic Encephalopathy Drugs Revenue by Application (2021-2026) & (US$ Million) Table 137. Europe Hepatic Encephalopathy Drugs Revenue by Application (2027-2032) & (US$ Million) Table 138. Europe Hepatic Encephalopathy Drugs Sales by Application (2021-2026) & (tons) Table 139. Europe Hepatic Encephalopathy Drugs Sales by Application (2027-2032) & (tons) Table 140. Europe Hepatic Encephalopathy Drugs Sales Price by Application (2021-2026) & (US$/kg) Table 141. Europe Hepatic Encephalopathy Drugs Sales Price by Application (2027-2032) & (US$/kg) Table 142. Europe Hepatic Encephalopathy Drugs Revenue Grow Rate by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 143. Europe Hepatic Encephalopathy Drugs Revenue Grow Rate by Country (2021-2026) & (US$ Million) Table 144. Europe Hepatic Encephalopathy Drugs Revenue Grow Rate by Country (2027-2032) & (US$ Million) Table 145. Europe Hepatic Encephalopathy Drugs Sales by Country (2021 VS 2025 VS 2032) & (tons) Table 146. Europe Hepatic Encephalopathy Drugs Sales by Country (2021-2026) & (tons) Table 147. Europe Hepatic Encephalopathy Drugs Sales by Country (2027-2032) & (tons) Table 148. Europe Hepatic Encephalopathy Drugs Sales Price by Country (2021-2026) & (US$/kg) Table 149. Europe Hepatic Encephalopathy Drugs Sales Price by Country (2027-2032) & (US$/kg) Table 150. Germany Hepatic Encephalopathy Drugs Revenue (2021-2032) & (US$ Million) Table 151. France Hepatic Encephalopathy Drugs Revenue (2021-2032) & (US$ Million) Table 152. U.K. Hepatic Encephalopathy Drugs Revenue (2021-2032) & (US$ Million) Table 153. Italy Hepatic Encephalopathy Drugs Revenue (2021-2032) & (US$ Million) Table 154. Russia Hepatic Encephalopathy Drugs Revenue (2021-2032) & (US$ Million) Table 155. Spain Hepatic Encephalopathy Drugs Revenue (2021-2032) & (US$ Million) Table 156. Netherlands Hepatic Encephalopathy Drugs Revenue (2021-2032) & (US$ Million) Table 157. Switzerland Hepatic Encephalopathy Drugs Revenue (2021-2032) & (US$ Million) Table 158. Sweden Hepatic Encephalopathy Drugs Revenue (2021-2032) & (US$ Million) Table 159. Poland Hepatic Encephalopathy Drugs Revenue (2021-2032) & (US$ Million) Table 160. China Hepatic Encephalopathy Drugs Revenue by Type (2021-2026) & (US$ Million) Table 161. China Hepatic Encephalopathy Drugs Revenue by Type (2027-2032) & (US$ Million) Table 162. China Hepatic Encephalopathy Drugs Sales by Type (2021-2026) & (tons) Table 163. China Hepatic Encephalopathy Drugs Sales by Type (2027-2032) & (tons) Table 164. China Hepatic Encephalopathy Drugs Sales Price by Type (2021-2026) & (US$/kg) Table 165. China Hepatic Encephalopathy Drugs Sales Price by Type (2027-2032) & (US$/kg) Table 166. China Hepatic Encephalopathy Drugs Revenue by Application (2021-2026) & (US$ Million) Table 167. China Hepatic Encephalopathy Drugs Revenue by Application (2027-2032) & (US$ Million) Table 168. China Hepatic Encephalopathy Drugs Sales by Application (2021-2026) & (tons) Table 169. China Hepatic Encephalopathy Drugs Sales by Application (2027-2032) & (tons) Table 170. China Hepatic Encephalopathy Drugs Sales Price by Application (2021-2026) & (US$/kg) Table 171. China Hepatic Encephalopathy Drugs Sales Price by Application (2027-2032) & (US$/kg) Table 172. Asia Hepatic Encephalopathy Drugs Revenue by Type (2021-2026) & (US$ Million) Table 173. Asia Hepatic Encephalopathy Drugs Revenue by Type (2027-2032) & (US$ Million) Table 174. Asia Hepatic Encephalopathy Drugs Sales by Type (2021-2026) & (tons) Table 175. Asia Hepatic Encephalopathy Drugs Sales by Type (2027-2032) & (tons) Table 176. Asia Hepatic Encephalopathy Drugs Sales Price by Type (2021-2026) & (US$/kg) Table 177. Asia Hepatic Encephalopathy Drugs Sales Price by Type (2027-2032) & (US$/kg) Table 178. Asia Hepatic Encephalopathy Drugs Revenue by Application (2021-2026) & (US$ Million) Table 179. Asia Hepatic Encephalopathy Drugs Revenue by Application (2027-2032) & (US$ Million) Table 180. Asia Hepatic Encephalopathy Drugs Sales by Application (2021-2026) & (tons) Table 181. Asia Hepatic Encephalopathy Drugs Sales by Application (2027-2032) & (tons) Table 182. Asia Hepatic Encephalopathy Drugs Sales Price by Application (2021-2026) & (US$/kg) Table 183. Asia Hepatic Encephalopathy Drugs Sales Price by Application (2027-2032) & (US$/kg) Table 184. Asia Hepatic Encephalopathy Drugs Revenue Grow Rate by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 185. Asia Hepatic Encephalopathy Drugs Revenue Grow Rate by Country (2021-2026) & (US$ Million) Table 186. Asia Hepatic Encephalopathy Drugs Revenue Grow Rate by Country (2027-2032) & (US$ Million) Table 187. Asia Hepatic Encephalopathy Drugs Sales by Country (2021 VS 2025 VS 2032) & (tons) Table 188. Asia Hepatic Encephalopathy Drugs Sales by Country (2021-2026) & (tons) Table 189. Asia Hepatic Encephalopathy Drugs Sales by Country (2027-2032) & (tons) Table 190. Asia Hepatic Encephalopathy Drugs Sales Price by Country (2021-2026) & (US$/kg) Table 191. Asia Hepatic Encephalopathy Drugs Sales Price by Country (2027-2032) & (US$/kg) Table 192. Japan Hepatic Encephalopathy Drugs Revenue (2021-2032) & (US$ Million) Table 193. South Korea Hepatic Encephalopathy Drugs Revenue (2021-2032) & (US$ Million) Table 194. India Hepatic Encephalopathy Drugs Revenue (2021-2032) & (US$ Million) Table 195. Australia Hepatic Encephalopathy Drugs Revenue (2021-2032) & (US$ Million) Table 196. Taiwan Hepatic Encephalopathy Drugs Revenue (2021-2032) & (US$ Million) Table 197. Southeast Asia Hepatic Encephalopathy Drugs Revenue (2021-2032) & (US$ Million) Table 198. SAMEA Hepatic Encephalopathy Drugs Revenue by Type (2021-2026) & (US$ Million) Table 199. SAMEA Hepatic Encephalopathy Drugs Revenue by Type (2027-2032) & (US$ Million) Table 200. SAMEA Hepatic Encephalopathy Drugs Sales by Type (2021-2026) & (tons) Table 201. SAMEA Hepatic Encephalopathy Drugs Sales by Type (2027-2032) & (tons) Table 202. SAMEA Hepatic Encephalopathy Drugs Sales Price by Type (2021-2026) & (US$/kg) Table 203. SAMEA Hepatic Encephalopathy Drugs Sales Price by Type (2027-2032) & (US$/kg) Table 204. SAMEA Hepatic Encephalopathy Drugs Revenue by Application (2021-2026) & (US$ Million) Table 205. SAMEA Hepatic Encephalopathy Drugs Revenue by Application (2027-2032) & (US$ Million) Table 206. SAMEA Hepatic Encephalopathy Drugs Sales by Application (2021-2026) & (tons) Table 207. SAMEA Hepatic Encephalopathy Drugs Sales by Application (2027-2032) & (tons) Table 208. SAMEA Hepatic Encephalopathy Drugs Sales Price by Application (2021-2026) & (US$/kg) Table 209. SAMEA Hepatic Encephalopathy Drugs Sales Price by Application (2027-2032) & (US$/kg) Table 210. SAMEA Hepatic Encephalopathy Drugs Revenue Grow Rate by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 211. SAMEA Hepatic Encephalopathy Drugs Revenue Grow Rate by Country (2021-2026) & (US$ Million) Table 212. SAMEA Hepatic Encephalopathy Drugs Revenue Grow Rate by Country (2027-2032) & (US$ Million) Table 213. SAMEA Hepatic Encephalopathy Drugs Sales by Country (2021 VS 2025 VS 2032) & (tons) Table 214. SAMEA Hepatic Encephalopathy Drugs Sales by Country (2021-2026) & (tons) Table 215. SAMEA Hepatic Encephalopathy Drugs Sales by Country (2027-2032) & (tons) Table 216. SAMEA Hepatic Encephalopathy Drugs Sales Price by Country (2021-2026) & (US$/kg) Table 217. SAMEA Hepatic Encephalopathy Drugs Sales Price by Country (2027-2032) & (US$/kg) Table 218. Brazil Hepatic Encephalopathy Drugs Revenue (2021-2032) & (US$ Million) Table 219. Argentina Hepatic Encephalopathy Drugs Revenue (2021-2032) & (US$ Million) Table 220. Chile Hepatic Encephalopathy Drugs Revenue (2021-2032) & (US$ Million) Table 221. Colombia Hepatic Encephalopathy Drugs Revenue (2021-2032) & (US$ Million) Table 222. Peru Hepatic Encephalopathy Drugs Revenue (2021-2032) & (US$ Million) Table 223. Saudi Arabia Hepatic Encephalopathy Drugs Revenue (2021-2032) & (US$ Million) Table 224. Israel Hepatic Encephalopathy Drugs Revenue (2021-2032) & (US$ Million) Table 225. UAE Hepatic Encephalopathy Drugs Revenue (2021-2032) & (US$ Million) Table 226. Turkey Hepatic Encephalopathy Drugs Revenue (2021-2032) & (US$ Million) Table 227. Iran Hepatic Encephalopathy Drugs Revenue (2021-2032) & (US$ Million) Table 228. Egypt Hepatic Encephalopathy Drugs Revenue (2021-2032) & (US$ Million) Table 229. Key Raw Materials Table 230. Raw Materials Key Suppliers Table 231. Hepatic Encephalopathy Drugs Distributors List Table 232. Hepatic Encephalopathy Drugs Customers List Table 233. Research Programs/Design for This Report Table 234. Authors List of This Report Table 235. Secondary Sources Table 236. Primary Sources List of Figures Figure 1. Hepatic Encephalopathy Drugs Image Figure 2. Global Hepatic Encephalopathy Drugs Market Size Growth Rate by Type (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Hepatic Encephalopathy Drugs Market Size Share 2021 VS 2025 VS 2032 Figure 4. Injection Image Figure 5. Oral Image Figure 6. Global Hepatic Encephalopathy Drugs Market Size Growth Rate by Application (US$ Million), 2021 VS 2025 VS 2032 Figure 7. Global Hepatic Encephalopathy Drugs Market Size Share 2021 VS 2025 VS 2032 Figure 8. Hospital Pharmacies Image Figure 9. Online Pharmacies Image Figure 10. Retail Pharmacies Image Figure 11. Global Hepatic Encephalopathy Drugs Revenue (US$ Million), 2021 VS 2025 VS 2032 Figure 12. Global Hepatic Encephalopathy Drugs Revenue (2021-2032) & (US$ Million) Figure 13. Global Hepatic Encephalopathy Drugs Revenue (CAGR) by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 14. Global Hepatic Encephalopathy Drugs Revenue Market Share by Region: 2025 Versus 2032 Figure 15. Global Hepatic Encephalopathy Drugs Revenue Market Share by Region (2021-2032) Figure 16. Global Hepatic Encephalopathy Drugs Sales (2021-2032) & (tons) Figure 17. Global Hepatic Encephalopathy Drugs Sales by Region: 2021 VS 2025 VS 2032 (tons) Figure 18. Global Hepatic Encephalopathy Drugs Sales Market Share by Region (2021-2032) Figure 19. US & Canada & Mexico Hepatic Encephalopathy Drugs Sales YoY (2021-2032) & (tons) Figure 20. Europe Hepatic Encephalopathy Drugs Sales YoY (2021-2032) & (tons) Figure 21. China Hepatic Encephalopathy Drugs Sales YoY (2021-2032) & (tons) Figure 22. Asia (Excluding China) Hepatic Encephalopathy Drugs Sales YoY (2021-2032) & (tons) Figure 23. South America, Middle East and Africa Hepatic Encephalopathy Drugs Sales YoY (2021-2032) & (tons) Figure 24. Global Hepatic Encephalopathy Drugs Manufacturers Revenue Share Top 10 and Top 5 in 2025 Figure 25. Global Hepatic Encephalopathy Drugs Manufacturers Sales Share Top 10 and Top 5 in 2025 Figure 26. Manufacturers Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 27. Global Hepatic Encephalopathy Drugs Revenue by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 28. Global Hepatic Encephalopathy Drugs Revenue Market Share by Type 2021 VS 2025 VS 2032 Figure 29. Global Hepatic Encephalopathy Drugs Revenue Market Share by Type (2021-2032) Figure 30. Global Hepatic Encephalopathy Drugs Sales by Type (2021 VS 2025 VS 2032) & (tons) Figure 31. Global Hepatic Encephalopathy Drugs Sales Market Share by Type 2021 VS 2025 VS 2032 Figure 32. Global Hepatic Encephalopathy Drugs Sales Market Share by Type (2021-2032) Figure 33. Global Hepatic Encephalopathy Drugs Revenue by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 34. Global Hepatic Encephalopathy Drugs Revenue Market Share by Application 2021 VS 2025 VS 2032 Figure 35. Global Hepatic Encephalopathy Drugs Revenue Market Share by Application (2021-2032) Figure 36. Global Hepatic Encephalopathy Drugs Sales by Application (2021 VS 2025 VS 2032) & (tons) Figure 37. Global Hepatic Encephalopathy Drugs Sales Market Share by Application 2021 VS 2025 VS 2032 Figure 38. Global Hepatic Encephalopathy Drugs Sales Market Share by Application (2021-2032) Figure 39. North America Hepatic Encephalopathy Drugs Revenue Share by Type (2021-2032) Figure 40. North America Hepatic Encephalopathy Drugs Sales Share by Type (2021-2032) Figure 41. North America Hepatic Encephalopathy Drugs Revenue Share by Application (2021-2032) Figure 42. North America Hepatic Encephalopathy Drugs Sales Share by Application (2021-2032) Figure 43. North America Hepatic Encephalopathy Drugs Revenue Share by Country (2021-2032) Figure 44. North America Hepatic Encephalopathy Drugs Sales Share by Country (2021-2032) Figure 45. Europe Hepatic Encephalopathy Drugs Revenue Share by Type (2021-2032) Figure 46. Europe Hepatic Encephalopathy Drugs Sales Share by Type (2021-2032) Figure 47. Europe Hepatic Encephalopathy Drugs Revenue Share by Application (2021-2032) Figure 48. Europe Hepatic Encephalopathy Drugs Sales Share by Application (2021-2032) Figure 49. Europe Hepatic Encephalopathy Drugs Revenue Share by Country (2021-2032) Figure 50. Europe Hepatic Encephalopathy Drugs Sales Share by Country (2021-2032) Figure 51. China Hepatic Encephalopathy Drugs Revenue Share by Type (2021-2032) Figure 52. China Hepatic Encephalopathy Drugs Sales Share by Type (2021-2032) Figure 53. China Hepatic Encephalopathy Drugs Revenue Share by Application (2021-2032) Figure 54. China Hepatic Encephalopathy Drugs Sales Share by Application (2021-2032) Figure 55. Asia Hepatic Encephalopathy Drugs Revenue Share by Type (2021-2032) Figure 56. Asia Hepatic Encephalopathy Drugs Sales Share by Type (2021-2032) Figure 57. Asia Hepatic Encephalopathy Drugs Revenue Share by Application (2021-2032) Figure 58. Asia Hepatic Encephalopathy Drugs Sales Share by Application (2021-2032) Figure 59. Asia Hepatic Encephalopathy Drugs Revenue Share by Country (2021-2032) Figure 60. Asia Hepatic Encephalopathy Drugs Sales Share by Country (2021-2032) Figure 61. SAMEA Hepatic Encephalopathy Drugs Revenue Share by Type (2021-2032) Figure 62. SAMEA Hepatic Encephalopathy Drugs Sales Share by Type (2021-2032) Figure 63. SAMEA Hepatic Encephalopathy Drugs Revenue Share by Application (2021-2032) Figure 64. SAMEA Hepatic Encephalopathy Drugs Sales Share by Application (2021-2032) Figure 65. SAMEA Hepatic Encephalopathy Drugs Revenue Share by Country (2021-2032) Figure 66. SAMEA Hepatic Encephalopathy Drugs Sales Share by Country (2021-2032) Figure 67. Hepatic Encephalopathy Drugs Value Chain Figure 68. Manufacturing Cost Structure Figure 69. Hepatic Encephalopathy Drugs Production Mode & Process Figure 70. Direct Comparison with Distribution Share Figure 71. Distributors Profiles Figure 72. Years Considered Figure 73. Research Process Figure 74. Key Executives Interviewed

Scope & coverage.

Types
  • Injection
  • Oral
Applications
  • Hospital Pharmacies
  • Online Pharmacies
  • Retail Pharmacies
Companies covered
  • Umecrine Cognition
  • Norgine
  • Mallinckrodt
  • Lupin
  • Kannalife Sciences
  • Kaleido Biosciences
  • Ferring Pharmaceuticals
  • Cosmo Pharmaceuticals
  • Bausch Health
  • ASKA Pharmaceutical

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Hepatic Encephalopathy Drugs Market by Type
  3. 1.2.1 Global Hepatic Encephalopathy Drugs Market Size by Type, 2021 VS 2025 VS 2032
  4. 1.2.2 Injection
  5. 1.2.3 Oral
  6. 1.3 Hepatic Encephalopathy Drugs Market by Application
  7. 1.3.1 Global Hepatic Encephalopathy Drugs Market Size by Application, 2021 VS 2025 VS 2032
  8. 1.3.2 Hospital Pharmacies
  9. 1.3.3 Online Pharmacies
  10. 1.3.4 Retail Pharmacies
  11. 1.4 Assumptions and Limitations
  12. 1.5 Study Goals and Objectives
2 Hepatic Encephalopathy Drugs Market Dynamics
  1. 2.1 Hepatic Encephalopathy Drugs Industry Trends
  2. 2.2 Hepatic Encephalopathy Drugs Industry Drivers
  3. 2.3 Hepatic Encephalopathy Drugs Industry Opportunities and Challenges
  4. 2.4 Hepatic Encephalopathy Drugs Industry Restraints
3 Global Market Growth Prospects
  1. 3.1 Global Hepatic Encephalopathy Drugs Revenue Estimates and Forecasts (2021-2032)
  2. 3.2 Global Hepatic Encephalopathy Drugs Revenue by Region
  3. 3.2.1 Global Hepatic Encephalopathy Drugs Revenue by Region: 2021 VS 2025 VS 2032
  4. 3.2.2 Global Hepatic Encephalopathy Drugs Revenue by Region (2021-2026)
  5. 3.2.3 Global Hepatic Encephalopathy Drugs Revenue by Region (2027-2032)
  6. 3.2.4 Global Hepatic Encephalopathy Drugs Revenue Market Share by Region (2021-2032)
  7. 3.3 Global Hepatic Encephalopathy Drugs Sales Estimates and Forecasts 2021-2032
  8. 3.4 Global Hepatic Encephalopathy Drugs Sales by Region
  9. 3.4.1 Global Hepatic Encephalopathy Drugs Sales by Region: 2021 VS 2025 VS 2032
  10. 3.4.2 Global Hepatic Encephalopathy Drugs Sales by Region (2021-2026)
  11. 3.4.3 Global Hepatic Encephalopathy Drugs Sales by Region (2027-2032)
  12. 3.4.4 Global Hepatic Encephalopathy Drugs Sales Market Share by Region (2021-2032)
  13. 3.5 US & Canada & Mexico
  14. 3.6 Europe
  15. 3.7 China
  16. 3.8 Asia (Excluding China)
  17. 3.9 South America, Middle East and Africa
4 Market Competitive Landscape by Manufacturers
  1. 4.1 Global Hepatic Encephalopathy Drugs Revenue by Manufacturers
  2. 4.1.1 Global Hepatic Encephalopathy Drugs Revenue by Manufacturers (2021-2026)
  3. 4.1.2 Global Hepatic Encephalopathy Drugs Revenue Market Share by Manufacturers (2021-2026)
  4. 4.1.3 Global Hepatic Encephalopathy Drugs Manufacturers Revenue Share Top 10 and Top 5 in 2025
  5. 4.2 Global Hepatic Encephalopathy Drugs Sales by Manufacturers
  6. 4.2.1 Global Hepatic Encephalopathy Drugs Sales by Manufacturers (2021-2026)
  7. 4.2.2 Global Hepatic Encephalopathy Drugs Sales Market Share by Manufacturers (2021-2026)
  8. 4.2.3 Global Hepatic Encephalopathy Drugs Manufacturers Sales Share Top 10 and Top 5 in 2025
  9. 4.3 Global Hepatic Encephalopathy Drugs Sales Price by Manufacturers (2021-2026)
  10. 4.4 Global Hepatic Encephalopathy Drugs Key Manufacturers Ranking, 2024 VS 2025 VS 2026
  11. 4.5 Global Hepatic Encephalopathy Drugs Key Manufacturers Manufacturing Sites & Headquarters
  12. 4.6 Global Hepatic Encephalopathy Drugs Manufacturers, Product Type & Application
  13. 4.7 Global Hepatic Encephalopathy Drugs Manufacturers' Establishment Date
  14. 4.8 Market Competitive Analysis
  15. 4.8.1 Global Hepatic Encephalopathy Drugs Market CR5 and HHI
  16. 4.8.2 2025 Hepatic Encephalopathy Drugs Tier 1, Tier 2, and Tier 3
5 Hepatic Encephalopathy Drugs Market by Type
  1. 5.1 Global Hepatic Encephalopathy Drugs Revenue by Type
  2. 5.1.1 Global Hepatic Encephalopathy Drugs Revenue by Type (2021 VS 2025 VS 2032)
  3. 5.1.2 Global Hepatic Encephalopathy Drugs Revenue by Type (2021-2032) & (US$ Million)
  4. 5.1.3 Global Hepatic Encephalopathy Drugs Revenue Market Share by Type (2021-2032)
  5. 5.2 Global Hepatic Encephalopathy Drugs Sales by Type
  6. 5.2.1 Global Hepatic Encephalopathy Drugs Sales by Type (2021 VS 2025 VS 2032)
  7. 5.2.2 Global Hepatic Encephalopathy Drugs Sales by Type (2021-2032) & (tons)
  8. 5.2.3 Global Hepatic Encephalopathy Drugs Sales Market Share by Type (2021-2032)
  9. 5.3 Global Hepatic Encephalopathy Drugs Price by Type
6 Hepatic Encephalopathy Drugs Market by Application
  1. 6.1 Global Hepatic Encephalopathy Drugs Revenue by Application
  2. 6.1.1 Global Hepatic Encephalopathy Drugs Revenue by Application (2021 VS 2025 VS 2032)
  3. 6.1.2 Global Hepatic Encephalopathy Drugs Revenue by Application (2021-2032) & (US$ Million)
  4. 6.1.3 Global Hepatic Encephalopathy Drugs Revenue Market Share by Application (2021-2032)
  5. 6.2 Global Hepatic Encephalopathy Drugs Sales by Application
  6. 6.2.1 Global Hepatic Encephalopathy Drugs Sales by Application (2021 VS 2025 VS 2032)
  7. 6.2.2 Global Hepatic Encephalopathy Drugs Sales by Application (2021-2032) & (tons)
  8. 6.2.3 Global Hepatic Encephalopathy Drugs Sales Market Share by Application (2021-2032)
  9. 6.3 Global Hepatic Encephalopathy Drugs Price by Application
7 Company Profiles
  1. 7.1 Umecrine Cognition
  2. 7.1.1 Umecrine Cognition Company Information
  3. 7.1.2 Umecrine Cognition Business Overview
  4. 7.1.3 Umecrine Cognition Hepatic Encephalopathy Drugs Sales, Revenue, Price and Gross Margin (2021-2026)
  5. 7.1.4 Umecrine Cognition Hepatic Encephalopathy Drugs Product Portfolio
  6. 7.1.5 Umecrine Cognition Recent Developments
  7. 7.2 Norgine
  8. 7.2.1 Norgine Company Information
  9. 7.2.2 Norgine Business Overview
  10. 7.2.3 Norgine Hepatic Encephalopathy Drugs Sales, Revenue, Price and Gross Margin (2021-2026)
  11. 7.2.4 Norgine Hepatic Encephalopathy Drugs Product Portfolio
  12. 7.2.5 Norgine Recent Developments
  13. 7.3 Mallinckrodt
  14. 7.3.1 Mallinckrodt Company Information
  15. 7.3.2 Mallinckrodt Business Overview
  16. 7.3.3 Mallinckrodt Hepatic Encephalopathy Drugs Sales, Revenue, Price and Gross Margin (2021-2026)
  17. 7.3.4 Mallinckrodt Hepatic Encephalopathy Drugs Product Portfolio
  18. 7.3.5 Mallinckrodt Recent Developments
  19. 7.4 Lupin
  20. 7.4.1 Lupin Company Information
  21. 7.4.2 Lupin Business Overview
  22. 7.4.3 Lupin Hepatic Encephalopathy Drugs Sales, Revenue, Price and Gross Margin (2021-2026)
  23. 7.4.4 Lupin Hepatic Encephalopathy Drugs Product Portfolio
  24. 7.4.5 Lupin Recent Developments
  25. 7.5 Kannalife Sciences
  26. 7.5.1 Kannalife Sciences Company Information
  27. 7.5.2 Kannalife Sciences Business Overview
  28. 7.5.3 Kannalife Sciences Hepatic Encephalopathy Drugs Sales, Revenue, Price and Gross Margin (2021-2026)
  29. 7.5.4 Kannalife Sciences Hepatic Encephalopathy Drugs Product Portfolio
  30. 7.5.5 Kannalife Sciences Recent Developments
  31. 7.6 Kaleido Biosciences
  32. 7.6.1 Kaleido Biosciences Company Information
  33. 7.6.2 Kaleido Biosciences Business Overview
  34. 7.6.3 Kaleido Biosciences Hepatic Encephalopathy Drugs Sales, Revenue, Price and Gross Margin (2021-2026)
  35. 7.6.4 Kaleido Biosciences Hepatic Encephalopathy Drugs Product Portfolio
  36. 7.6.5 Kaleido Biosciences Recent Developments
  37. 7.7 Ferring Pharmaceuticals
  38. 7.7.1 Ferring Pharmaceuticals Company Information
  39. 7.7.2 Ferring Pharmaceuticals Business Overview
  40. 7.7.3 Ferring Pharmaceuticals Hepatic Encephalopathy Drugs Sales, Revenue, Price and Gross Margin (2021-2026)
  41. 7.7.4 Ferring Pharmaceuticals Hepatic Encephalopathy Drugs Product Portfolio
  42. 7.7.5 Ferring Pharmaceuticals Recent Developments
  43. 7.8 Cosmo Pharmaceuticals
  44. 7.8.1 Cosmo Pharmaceuticals Company Information
  45. 7.8.2 Cosmo Pharmaceuticals Business Overview
  46. 7.8.3 Cosmo Pharmaceuticals Hepatic Encephalopathy Drugs Sales, Revenue, Price and Gross Margin (2021-2026)
  47. 7.8.4 Cosmo Pharmaceuticals Hepatic Encephalopathy Drugs Product Portfolio
  48. 7.8.5 Cosmo Pharmaceuticals Recent Developments
  49. 7.9 Bausch Health
  50. 7.9.1 Bausch Health Company Information
  51. 7.9.2 Bausch Health Business Overview
  52. 7.9.3 Bausch Health Hepatic Encephalopathy Drugs Sales, Revenue, Price and Gross Margin (2021-2026)
  53. 7.9.4 Bausch Health Hepatic Encephalopathy Drugs Product Portfolio
  54. 7.9.5 Bausch Health Recent Developments
  55. 7.10 ASKA Pharmaceutical
  56. 7.10.1 ASKA Pharmaceutical Company Information
  57. 7.10.2 ASKA Pharmaceutical Business Overview
  58. 7.10.3 ASKA Pharmaceutical Hepatic Encephalopathy Drugs Sales, Revenue, Price and Gross Margin (2021-2026)
  59. 7.10.4 ASKA Pharmaceutical Hepatic Encephalopathy Drugs Product Portfolio
  60. 7.10.5 ASKA Pharmaceutical Recent Developments
8 North America
  1. 8.1 North America Hepatic Encephalopathy Drugs Market Size by Type
  2. 8.1.1 North America Hepatic Encephalopathy Drugs Revenue by Type (2021-2032)
  3. 8.1.2 North America Hepatic Encephalopathy Drugs Sales by Type (2021-2032)
  4. 8.1.3 North America Hepatic Encephalopathy Drugs Price by Type (2021-2032)
  5. 8.2 North America Hepatic Encephalopathy Drugs Market Size by Application
  6. 8.2.1 North America Hepatic Encephalopathy Drugs Revenue by Application (2021-2032)
  7. 8.2.2 North America Hepatic Encephalopathy Drugs Sales by Application (2021-2032)
  8. 8.2.3 North America Hepatic Encephalopathy Drugs Price by Application (2021-2032)
  9. 8.3 North America Hepatic Encephalopathy Drugs Market Size by Country
  10. 8.3.1 North America Hepatic Encephalopathy Drugs Revenue Grow Rate by Country (2021 VS 2025 VS 2032)
  11. 8.3.2 North America Hepatic Encephalopathy Drugs Sales by Country (2021 VS 2025 VS 2032)
  12. 8.3.3 North America Hepatic Encephalopathy Drugs Price by Country (2021-2032)
  13. 8.3.4 United States
  14. 8.3.5 Canada
  15. 8.3.6 Mexico
9 Europe
  1. 9.1 Europe Hepatic Encephalopathy Drugs Market Size by Type
  2. 9.1.1 Europe Hepatic Encephalopathy Drugs Revenue by Type (2021-2032)
  3. 9.1.2 Europe Hepatic Encephalopathy Drugs Sales by Type (2021-2032)
  4. 9.1.3 Europe Hepatic Encephalopathy Drugs Price by Type (2021-2032)
  5. 9.2 Europe Hepatic Encephalopathy Drugs Market Size by Application
  6. 9.2.1 Europe Hepatic Encephalopathy Drugs Revenue by Application (2021-2032)
  7. 9.2.2 Europe Hepatic Encephalopathy Drugs Sales by Application (2021-2032)
  8. 9.2.3 Europe Hepatic Encephalopathy Drugs Price by Application (2021-2032)
  9. 9.3 Europe Hepatic Encephalopathy Drugs Market Size by Country
  10. 9.3.1 Europe Hepatic Encephalopathy Drugs Revenue Grow Rate by Country (2021 VS 2025 VS 2032)
  11. 9.3.2 Europe Hepatic Encephalopathy Drugs Sales by Country (2021 VS 2025 VS 2032)
  12. 9.3.3 Europe Hepatic Encephalopathy Drugs Price by Country (2021-2032)
  13. 9.3.4 Germany
  14. 9.3.5 France
  15. 9.3.6 U.K.
  16. 9.3.7 Italy
  17. 9.3.8 Russia
  18. 9.3.9 Spain
  19. 9.3.10 Netherlands
10 China
  1. 10.1 China Hepatic Encephalopathy Drugs Market Size by Type
  2. 10.1.1 China Hepatic Encephalopathy Drugs Revenue by Type (2021-2032)
  3. 10.1.2 China Hepatic Encephalopathy Drugs Sales by Type (2021-2032)
  4. 10.1.3 China Hepatic Encephalopathy Drugs Price by Type (2021-2032)
  5. 10.2 China Hepatic Encephalopathy Drugs Market Size by Application
  6. 10.2.1 China Hepatic Encephalopathy Drugs Revenue by Application (2021-2032)
  7. 10.2.2 China Hepatic Encephalopathy Drugs Sales by Application (2021-2032)
  8. 10.2.3 China Hepatic Encephalopathy Drugs Price by Application (2021-2032)
11 Asia (Excluding China)
  1. 11.1 Asia Hepatic Encephalopathy Drugs Market Size by Type
  2. 11.1.1 Asia Hepatic Encephalopathy Drugs Revenue by Type (2021-2032)
  3. 11.1.2 Asia Hepatic Encephalopathy Drugs Sales by Type (2021-2032)
  4. 11.1.3 Asia Hepatic Encephalopathy Drugs Price by Type (2021-2032)
  5. 11.2 Asia Hepatic Encephalopathy Drugs Market Size by Application
  6. 11.2.1 Asia Hepatic Encephalopathy Drugs Revenue by Application (2021-2032)
  7. 11.2.2 Asia Hepatic Encephalopathy Drugs Sales by Application (2021-2032)
  8. 11.2.3 Asia Hepatic Encephalopathy Drugs Price by Application (2021-2032)
  9. 11.3 Asia Hepatic Encephalopathy Drugs Market Size by Country
  10. 11.3.1 Asia Hepatic Encephalopathy Drugs Revenue Grow Rate by Country (2021 VS 2025 VS 2032)
  11. 11.3.2 Asia Hepatic Encephalopathy Drugs Sales by Country (2021 VS 2025 VS 2032)
  12. 11.3.3 Asia Hepatic Encephalopathy Drugs Price by Country (2021-2032)
  13. 11.3.4 Japan
  14. 11.3.5 South Korea
  15. 11.3.6 India
  16. 11.3.7 Australia
  17. 11.3.8 Taiwan
  18. 11.3.9 Southeast Asia
12 South America, Middle East and Africa
  1. 12.1 SAMEA Hepatic Encephalopathy Drugs Market Size by Type
  2. 12.1.1 SAMEA Hepatic Encephalopathy Drugs Revenue by Type (2021-2032)
  3. 12.1.2 SAMEA Hepatic Encephalopathy Drugs Sales by Type (2021-2032)
  4. 12.1.3 SAMEA Hepatic Encephalopathy Drugs Price by Type (2021-2032)
  5. 12.2 SAMEA Hepatic Encephalopathy Drugs Market Size by Application
  6. 12.2.1 SAMEA Hepatic Encephalopathy Drugs Revenue by Application (2021-2032)
  7. 12.2.2 SAMEA Hepatic Encephalopathy Drugs Sales by Application (2021-2032)
  8. 12.2.3 SAMEA Hepatic Encephalopathy Drugs Price by Application (2021-2032)
  9. 12.3 SAMEA Hepatic Encephalopathy Drugs Market Size by Country
  10. 12.3.1 SAMEA Hepatic Encephalopathy Drugs Revenue Grow Rate by Country (2021 VS 2025 VS 2032)
  11. 12.3.2 SAMEA Hepatic Encephalopathy Drugs Sales by Country (2021 VS 2025 VS 2032)
  12. 12.3.3 SAMEA Hepatic Encephalopathy Drugs Price by Country (2021-2032)
  13. 12.3.4 Brazil
  14. 12.3.5 Argentina
  15. 12.3.6 Chile
  16. 12.3.7 Colombia
  17. 12.3.8 Peru
  18. 12.3.9 Saudi Arabia
  19. 12.3.10 Israel
  20. 12.3.11 UAE
  21. 12.3.12 Turkey
  22. 12.3.13 Iran
  23. 12.3.14 Egypt
13 Value Chain and Sales Channels Analysis
  1. 13.1 Hepatic Encephalopathy Drugs Value Chain Analysis
  2. 13.1.1 Hepatic Encephalopathy Drugs Key Raw Materials
  3. 13.1.2 Raw Materials Key Suppliers
  4. 13.1.3 Manufacturing Cost Structure
  5. 13.1.4 Hepatic Encephalopathy Drugs Production Mode & Process
  6. 13.2 Hepatic Encephalopathy Drugs Sales Channels Analysis
  7. 13.2.1 Direct Comparison with Distribution Share
  8. 13.2.2 Hepatic Encephalopathy Drugs Distributors
  9. 13.2.3 Hepatic Encephalopathy Drugs Customers
14 Concluding Insights
    15 Appendix
    1. 15.1 Reasons for Doing This Study
    2. 15.2 Research Methodology
    3. 15.3 Research Process
    4. 15.4 Authors List of This Report
    5. 15.5 Data Source
    6. 15.5.1 Secondary Sources
    7. 15.5.2 Primary Sources
    8. 15.6 Disclaimer

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,950USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst